JP Patent

JP7507093B2 — １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法

Assigned to Regeneron Pharmaceuticals Inc · Expires 2024-06-27 · 2y expired

What this patent protects

Patent listed against givosiran-sodium.

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: JP7507093B2
Jurisdiction: JP
Classification: —
Expires: 2024-06-27
Drug substance claim: No
Drug product claim: No
Assignee: Regeneron Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.